Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy

被引:48
|
作者
Petrova, N. L. [1 ]
Dew, T. K. [2 ]
Musto, R. L. [2 ]
Sherwood, R. A. [2 ]
Bates, M. [1 ]
Moniz, C. F. [2 ]
Edmonds, M. E. [1 ]
机构
[1] Kings Coll Hosp NHS Fdn Trust, Diabet Foot Clin, London, England
[2] Kings Coll Hosp NHS Fdn Trust, Dept Clin Biochem, London, England
关键词
NEUROPATHIC OSTEOARTHROPATHY; PROINFLAMMATORY CYTOKINES; NEURO-OSTEOARTHROPATHY; MINERAL DENSITY; FOOT; OSTEOPROTEGERIN; RESORPTION; DIAGNOSIS; TYPE-1;
D O I
10.1111/dme.12590
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsTo assess markers of inflammation and bone turnover at presentation and at resolution of Charcot osteoarthropathy. MethodsWe measured serum inflammatory and bone turnover markers in a cross-sectional study of 35 people with Charcot osteoarthropathy, together with 34 people with diabetes and 12 people without diabetes. In addition, a prospective study of the subjects with Charcot osteoarthropathy was conducted until clinical resolution. ResultsAt presentation, C-reactive protein (P=0.007), tumour necrosis factor- (P=0.010) and interleukin-6 (P=0.002), but not interleukin-1, (P=0.254) were significantly higher in people with Charcot osteoarthropathy than in people with and without diabetes. Serum C-terminal telopeptide (P=0.004), bone alkaline phosphatase (P=0.006) and osteoprotegerin (P<0.001), but not tartrate-resistant acid phosphatase (P=0.126) and soluble receptor activator of nuclear factor- ligand (P=0.915), were significantly higher in people with Charcot osteoarthropathy than in people with and without diabetes. At follow-up it was found that tumour necrosis factor- (P=0.012) and interleukin-6 (P=0.003), but not C-reactive protein (P=0.101), interleukin-1 (P=0.457), C-terminal telopeptide (P=0.743), bone alkaline phosphatase (P=0.193), tartrate-resistant acid phosphatase (P=0.856), osteoprotegerin (P=0.372) or soluble receptor activator of nuclear factor-k ligand (P=0.889), had significantly decreased between presentation and the 3months of casting therapy time point, and all analytes remained unchanged from 3months of casting therapy until resolution. In people with Charcot osteoarthropathy, there was a positive correlation between interleukin-6 and C-terminal telopeptide (P=0.028) and tumour necrosis factor- and C-terminal telopeptide (P=0.013) only at presentation. ConclusionsAt the onset of acute Charcot foot, serum concentrations of tumour necrosis factor- and interleukin-6 were elevated; however, there was a significant reduction in these markers at resolution and these markers may be useful in the assessment of disease activity. .
引用
收藏
页码:267 / 273
页数:7
相关论文
共 50 条
  • [1] A Prospective Study of Calcaneal Bone Mineral Density in Acute Charcot Osteoarthropathy
    Petrova, Nina L.
    Edmonds, Michael. E.
    [J]. DIABETES CARE, 2010, 33 (10) : 2254 - 2256
  • [2] Physical Activity and Bone Turnover Markers: A Cross-Sectional and a Longitudinal Study
    Adami, Silvano
    Gatti, Davide
    Viapiana, Ombretta
    Fiore, Carmelo Erio
    Nuti, Ranuccio
    Luisetto, Giovanni
    Ponte, Marco
    Rossini, Maurizio
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2008, 83 (06) : 388 - 392
  • [3] Physical Activity and Bone Turnover Markers: A Cross-Sectional and a Longitudinal Study
    Silvano Adami
    Davide Gatti
    Ombretta Viapiana
    Carmelo Erio Fiore
    Ranuccio Nuti
    Giovanni Luisetto
    Marco Ponte
    Maurizio Rossini
    [J]. Calcified Tissue International, 2008, 83 : 388 - 392
  • [4] A cross-sectional study of bone turnover markers in healthy premenopausal women
    de Papp, Anne E.
    Bone, Henry G.
    Caulfield, Michael P.
    Kagan, Risa
    Buinewicz, Anna
    Chen, Erluo
    Rosenberg, Elizabeth
    Reitz, Richard E.
    [J]. BONE, 2007, 40 (05) : 1222 - 1230
  • [5] Bone turnover markers in acute Charcot neuroarthropathy
    Selby, PL
    Jude, EB
    Burgess, J
    Page, S
    Edmonds, ME
    Foster, A
    Mawer, EB
    Adams, JE
    Boulton, AJM
    [J]. DIABETOLOGIA, 1998, 41 : A275 - A275
  • [6] Biochemical markers of bone remodeling in diagnosis of acute Charcot osteoarthropathy and osteomyelitis
    Ulianova, I
    Tokmakova, A
    Antsiferov, M
    [J]. DIABETOLOGIA, 2002, 45 : A342 - A342
  • [7] Serum markers of bone turnover: A novel approach to monitoring the natural history of charcot osteoarthropathy
    Moniz, C.
    Musto, R.
    Petrova, N.
    Edmunds, M.
    Langworthy, R.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (07) : 1139 - 1139
  • [8] Positive association of glucagon with bone turnover markers in type 2 diabetes: A cross-sectional study
    Guo, Hui
    Sui, Chunhua
    Ge, Shaohong
    Cai, Jian
    Lin, Dongping
    Guo, Yuyu
    Wang, Ningjian
    Zhou, Ying
    Ying, Rong
    Zha, Kexi
    Gu, Tao
    Zhao, Yan
    Lu, Yingli
    An, Zengmei
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2022, 38 (06)
  • [9] Biochemical markers of bone turnover in patients with thyroid dysfunctions and in euthyroid controls: a cross-sectional study
    Engler, H
    Oettli, RE
    Riesen, WF
    [J]. CLINICA CHIMICA ACTA, 1999, 289 (1-2) : 159 - 172
  • [10] Reference intervals of biochemical bone turnover markers for Saudi Arabian women: A cross-sectional study
    Ardawi, Mohammed-Salleh M.
    Maimani, Abdulrauf A.
    Bahksh, Talal A.
    Rouzi, Abdulraheem A.
    Qari, Mohammed H.
    Raddadi, Rajaa M.
    [J]. BONE, 2010, 47 (04) : 804 - 814